Table 1:
RRMS (n = 43) | SPMS (n = 15) | P Valuea | |
---|---|---|---|
Women (No.) (%) | 38 (88.4) | 11 (73.3) | .658 |
Age (mean) (SD) (yr) | 52.8 (12.1) | 60.5 (6.7) | .023b |
Disease duration (mean) (SD) (yr) | 15.2 (8.9) | 21.9 (8.3) | .014b |
EDSS (median) (IQR) | 3.0 (2.0–3.5) | 6.0 (3.6–6.5) | .003b |
Age at onset (mean) (SD) (yr) | 37.6 (12.0) | 38.7 (8.5) | .428 |
Disease-modifying therapy (No.) (%) | |||
Interferon β-1a I.M. | 14 (32.6) | 2 (13.3) | .111 |
Interferon β-1a S.C. | 3 (9.3) | 0 (0) | |
Glatiramer acetate | 8 (18.6) | 2 (13.3) | |
Natalizumab | 4 (9.3) | 1 (6.7) | |
Dimethyl fumarate | 2 (4.7) | 0 (0) | |
Fingolimod | 3 (7.0) | 0 (0) | |
Teriflunomide | 1 (2.3) | 3 (20.0) | |
Rituximab | 1 (2.3) | 0 (0) | |
Ocrelizumab | 0 (0) | 1 (6.7) | |
IVIG | 1 (2.3) | 1 (6.7) | |
No therapy | 6 (14.0) | 5 (33.3) | |
No. of LMCE foci | 1 (n = 33) | 1 (n = 8) | .292 |
2 (n = 8) | 2 (n = 4) | ||
3 (n = 2) | 3 (n = 3) | ||
LMCE shape (No.) | .637 | ||
Nodular | 36 | 16 | |
Linear | 7 | 5 | |
Plate-like | 12 | 4 | |
T2 lesion volume (mean) (SD) (mL) | 16.0 (16.2) | 15.8 (11.4) | .965 |
Gd lesion volume (median) (IQR) (mL) | 0 (0–0) | 0 (0–0) | .097 |
Note:—EDSS indicates Expanded Disability Status Scale; I.M., intramuscular; S.C., subcutaneous; IVIG, intravenous immunoglobulin; Gd, gadolinium.
P value represents differences between the patients with RRMS and SPMS. The differences between the groups were analyzed using the Fisher exact, Student t, Mann-Whitney U, or χ2 test.
P values < .05.